G. D. Searle & Company
An American pharmaceutical company remembered for Enovid, NutraSweet, Lomotil, and the development of celecoxib.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
G. D. Searle & Company, commonly known as Searle, was an American pharmaceutical and life-sciences company founded by Gideon Daniel Searle in Omaha, Nebraska, in 1888. The business incorporated in 1908 and later established its headquarters in Skokie, Illinois, in 1941. Over the course of the twentieth century, Searle developed and commercialized prescription medicines, consumer health products, artificial sweeteners, and other life-science offerings. Its history illustrates the transition of a family-founded pharmaceutical business into a major research-oriented company and, ultimately, into the portfolio of larger multinational corporations. Searle became particularly prominent through products that had effects well beyond the pharmaceutical sector. In 1960, it introduced Enovid, generally recognized as the first commercially approved oral contraceptive. The product helped establish the modern birth-control-pill market and made Searle a central participant in one of the most consequential developments in reproductive health. The company also developed aspartame, later commercialized under the NutraSweet brand. Regulatory developments eventually permitted broader use of aspartame, including in heated and baked foods, and the associated intellectual-property rights became an important part of Searle's commercial history. Other recognized Searle products included Lomotil, an antidiarrheal medicine, and Dramamine and Metamucil among its better-known pharmaceutical or consumer-health offerings. Before its 1985 merger with Monsanto, Searle operated across several life-science areas, including pharmaceuticals, agriculture, and animal health. Its management and scientific organization also produced alumni who later became influential outside the company. Daniel C. Searle served as president and chief executive from 1970 to 1977 and was involved in efforts to secure regulatory approval for aspartame. Donald Rumsfeld led the company as chief executive and president from 1977 to 1985, then negotiated its acquisition by Monsanto. Searle's research organization remained significant after the Monsanto transaction. In 1993, Searle researchers filed a patent application for celecoxib, a selective cyclooxygenase-2 inhibitor. The medicine received United States Food and Drug Administration approval on December 31, 1998, becoming the first selective COX-2 inhibitor approved by the FDA. Celecoxib became a major pharmaceutical product and later figured prominently in the strategic value attributed to Searle's pharmaceutical assets. Monsanto combined with Pharmacia & Upjohn in 2001. The resulting corporate structure retained Searle pharmaceutical assets while Monsanto's agrochemical and biotechnology operations were separated under the Monsanto name. The pharmaceutical business became associated with Pharmacia, which Pfizer acquired in 2003. Consequently, Searle ceased to operate as an independent company, although products and intellectual property originating in its research and commercial organization continued within successor portfolios. The Searle name is therefore principally historical: it remains associated with the development of oral contraception, aspartame, antidiarrheal therapy, and celecoxib rather than with a current standalone operating brand.
History
Gideon Daniel Searle founded the company in Omaha, Nebraska, in 1888. It incorporated in 1908 and expanded its organizational base over the following decades. In 1941, the company established its headquarters in Skokie, Illinois. Searle developed as a diversified life-sciences enterprise, with activities spanning pharmaceuticals, agriculture, and animal health before its merger with Monsanto. The company gained lasting recognition from products that combined pharmaceutical research with broad public-health and consumer significance. Enovid, introduced in 1960, is widely identified as the first commercially approved oral contraceptive. Its launch placed Searle at the center of the emerging birth-control-pill industry and helped define the company's historical reputation. Searle also developed aspartame, later marketed as NutraSweet. The company's patent position on aspartame was extended in 1981 and expired in December 1992. In 1996, the FDA removed restrictions that had limited its use in heated and baked foods. Searle's other recognized products included Lomotil, an antidiarrheal medicine, as well as Dramamine and Metamucil. Leadership during the 1970s and 1980s connected the company with both pharmaceutical management and wider American public life. Daniel C. Searle served as president and chief executive from 1970 through 1977 and was involved in efforts to obtain FDA approval for aspartame. Donald Rumsfeld succeeded him as chief executive and president, serving from 1977 to 1985. Rumsfeld negotiated Monsanto's acquisition of Searle in 1985, ending the company's independence while preserving its pharmaceutical research and product assets within a larger life-sciences corporation. Searle's research contribution continued to be important after the Monsanto transaction. In 1993, researchers at Searle Research and Development filed a patent application for celecoxib. The compound became the first selective COX-2 inhibitor approved by the FDA when it received approval on December 31, 1998. Celecoxib's commercial potential and Searle's related pharmaceutical assets were later regarded as important elements in the value of the business inherited through successive corporate combinations. Monsanto merged with Pharmacia & Upjohn in 2001. After the agricultural and biotechnology units were separated under the Monsanto name, the pharmaceutical operations were associated with Pharmacia. Pfizer acquired Pharmacia in 2003. The transaction transferred Searle-originated medicines and intellectual property into Pfizer's portfolio and removed Searle as an independent corporate entity. The company is now best understood as a historical pharmaceutical brand and predecessor business rather than an active standalone manufacturer.
- 2003
Pfizer acquires Pharmacia
[1]Pfizer acquired Pharmacia, ultimately absorbing the former Searle pharmaceutical portfolio.
- 2001
Searle assets enter Pharmacia structure
[1]The Monsanto and Pharmacia & Upjohn combination placed Searle pharmaceutical assets within the resulting Pharmacia organization.
- 1998
Celecoxib approved by the FDA
[1]Celecoxib became the first selective COX-2 inhibitor approved by the FDA on December 31.
- 1993
Celecoxib patent application filed
[1]Searle Research and Development researchers filed a patent application for celecoxib.
- 1985
Acquired by Monsanto
[1]Donald Rumsfeld negotiated Monsanto's acquisition of Searle, ending its independence.
- 1981
Aspartame patent extended
[1]Searle's patent rights for aspartame were extended, supporting the NutraSweet business before eventual expiration.
- 1960
Enovid introduced
[1]Searle released Enovid, recognized as the first commercially approved oral contraceptive.
- 1941
Headquarters established in Skokie
[1]Searle established its headquarters in Skokie, Illinois.
- 1908
Incorporation
[1]The business was incorporated as it developed from its founder's pharmaceutical enterprise into a larger company.
- 1888
Company founded in Omaha
[1]Gideon Daniel Searle founded the company in Omaha, Nebraska.
Products and positioning
A research-driven American life-sciences company whose reputation was built on important pharmaceutical innovations and widely recognized consumer-health products.
Oral contraceptive · 1960
Enovid
Enovid was Searle's landmark oral contraceptive, introduced in 1960 and widely recognized as the first commercially approved birth-control pill. Its release made Searle a defining company in the early modern contraceptive market and gave the business an enduring place in pharmaceutical and reproductive-health history.
Artificial sweetener
NutraSweet
NutraSweet was the commercial brand associated with aspartame developed by Searle. The ingredient became a widely used low-calorie sweetener. Patent and regulatory developments, including expanded FDA permissions in 1996, shaped its commercialization and made it one of Searle's best-known non-prescription consumer products.
Antidiarrheal medicine
Lomotil
Lomotil was an antidiarrheal medication developed by Searle. It represents the company's conventional prescription-pharmaceutical business alongside its more publicly prominent contraceptive and sweetener innovations.
Consumer health medicine
Dramamine
Dramamine was among the recognized pharmaceutical and consumer-health products associated with Searle. The product broadened the company's visibility beyond specialist prescription medicines and formed part of its diversified health-product portfolio.
Fiber supplement
Metamucil
Metamucil was another well-known consumer-health product associated with Searle. Its inclusion in the company's portfolio illustrates Searle's presence in products sold directly to consumers as well as in prescription therapeutics.
Selective COX-2 inhibitor · 1998
Celecoxib
Celecoxib was developed by Searle researchers and became the first selective COX-2 inhibitor approved by the FDA, on December 31, 1998. Its clinical and commercial importance made the compound one of the most valuable pharmaceutical outcomes of Searle's research organization and contributed to the strategic significance of the assets later acquired by Pfizer through Pharmacia.
Brand decisions
2003
Pfizer acquires Pharmacia and absorbs Searle heritage assetsM&ABackground
Searle's pharmaceutical business had passed through Monsanto and the Pharmacia structure after the 1985 acquisition and 2001 combination.
Action taken
Pfizer acquired Pharmacia, bringing the former Searle portfolio and related intellectual property into Pfizer.
Aftermath
The Searle name no longer represented an independent operating pharmaceutical company.
2001
Pharmacia & Upjohn combination reorganizes Searle assetsM&ABackground
Monsanto combined with Pharmacia & Upjohn as part of a broader restructuring of life-sciences businesses.
Action taken
The Searle pharmaceutical assets were included in the new corporate structure, while Monsanto's agricultural and biotechnology businesses were separated under the Monsanto name.
Aftermath
The pharmaceutical operations became associated with Pharmacia and were subsequently acquired by Pfizer.
1985
Searle agrees to Monsanto acquisitionM&ABackground
Searle had operated as a diversified life-sciences company with pharmaceutical, agricultural, and animal-health interests. Its leadership pursued a transaction that would place the business within Monsanto.
Action taken
Chief executive and president Donald Rumsfeld negotiated Monsanto's acquisition of Searle.
Aftermath
Searle ceased to be an independent company, while its pharmaceutical research and product assets continued through Monsanto and later corporate successors.
Recent events
- 2003
Pfizer acquires Pharmacia[1]
M&A
Pfizer acquired Pharmacia, bringing the former Searle pharmaceutical assets and associated products into Pfizer's portfolio and ending Searle's independent corporate identity.
- 2001
Pharmacia & Upjohn combination brings Searle pharmaceutical assets into the Pharmacia structure[1]
M&A
Monsanto combined with Pharmacia & Upjohn, and Searle's pharmaceutical assets became part of the resulting corporate structure while Monsanto's agricultural and biotechnology operations were separated under the Monsanto name.
- 1998
Celecoxib receives FDA approval[1]
Product launch · Regulation
Celecoxib, developed by Searle researchers, became the first selective COX-2 inhibitor approved by the FDA on December 31, 1998.
- 1996
FDA removes remaining restrictions on aspartame use[1]
Regulation · Product generation
The FDA removed restrictions that had limited aspartame's use in heated and baked foods, expanding the potential applications of the ingredient associated with Searle's NutraSweet business.
- 1960
Searle launches Enovid, the first commercial oral contraceptive[1]
Product launch · Other
Searle introduced Enovid, a milestone product in the development of the modern oral contraceptive market.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/g-d-searle-and-company · Editorial policy · How profiles are compiled